|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
JMJD2A-specific siRNA was chemically synthesised and transfected into human breast cancer cell line MDA-MB-231.
|
21962223 |
2011 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
JMJD2A-specific siRNA was chemically synthesised and transfected into human breast cancer cell line MDA-MB-231.
|
21962223 |
2011 |
|
Carcinogenesis
|
0.090 |
AlteredExpression
|
phenotype |
BEFREE |
JMJD2A is a transcriptional cofactor and enzyme that catalyzes demethylation of histone H3 lysines 9 and 36 and is overexpressed in human tumors, but its role in oncogenesis remains unclear.
|
22134899 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5.
|
23168260 |
2012 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
JMJD2A predicts prognosis and regulates cell growth in human gastric cancer.
|
24802408 |
2014 |
|
Stomach Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
JMJD2A predicts prognosis and regulates cell growth in human gastric cancer.
|
24802408 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
JMJD2A expression is associated with tumor stage and nodal status, and high level of JMJD2A predicts poor overall and disease-free survival.
|
24802408 |
2014 |
|
Advanced breast cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
JMJD2A-dependent silencing of Sp1 in advanced breast cancer promotes metastasis by downregulation of DIRAS3.
|
25193278 |
2014 |
|
Neoplasm Metastasis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
JMJD2A-dependent silencing of Sp1 in advanced breast cancer promotes metastasis by downregulation of DIRAS3.
|
25193278 |
2014 |
|
Malignant neoplasm of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Jumonji domain containing 2A predicts prognosis and regulates cell growth in lung cancer depending on miR-150.
|
26498874 |
2016 |
|
Carcinoma of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Jumonji domain containing 2A predicts prognosis and regulates cell growth in lung cancer depending on miR-150.
|
26498874 |
2016 |
|
Primary malignant neoplasm of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Jumonji domain containing 2A predicts prognosis and regulates cell growth in lung cancer depending on miR-150.
|
26498874 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
KDM4A SNP-A482 had a minor allele (C) frequency of 18.8% and a major allele (A) frequency of 81.2% in our Asian NSCLC (adenocarcinoma) patients.
|
28059867 |
2017 |
|
Nasopharyngeal carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
JMJD2A was expressed at high levels in NPC tumor tissues and cell lines.
|
28693517 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
KDM4A gene expression was higher in CLL patients as compared with control samples.
|
30426231 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
JMJD2A increased cervical cancer cell and colony numbers in vitro, increased the tumor weight in a mouse xenograft model, and decreased the apoptotic rate by downregulating the pro‑apoptotic proteins Bax, p21 and active caspase‑3, and upregulating the anti‑apoptotic protein Bcl‑2.
|
30720092 |
2019 |
|
Carcinogenesis
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
Jumonji domain-containing protein 2A (JMJD2A) of the JMJD2 family of histone lysine demethylases has been implicated in tumorigenesis.
|
31677131 |
2019 |
|
Malignant neoplasm of stomach
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
JMJD2A was universally expressed in 12 GC cell lines, and its overexpression in GC tissue was positively correlated with tumor regression in 34 DCS-treated patients.
|
31677131 |
2019 |
|
Stomach Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
JMJD2A was universally expressed in 12 GC cell lines, and its overexpression in GC tissue was positively correlated with tumor regression in 34 DCS-treated patients.
|
31677131 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
JMJD2A was universally expressed in 12 GC cell lines, and its overexpression in GC tissue was positively correlated with tumor regression in 34 DCS-treated patients.
|
31677131 |
2019 |
|
Triglyceride storage disease with ichthyosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
JMJD2A was universally expressed in 12 GC cell lines, and its overexpression in GC tissue was positively correlated with tumor regression in 34 DCS-treated patients.
|
31677131 |
2019 |
|
Prostatic Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
A corollary is that KDM4A as well as YAP1 inhibitors may prove beneficial for the therapy of ERG-overexpressing prostate tumors.
|
27109047 |
2016 |
|
Prostatic Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Additionally, JMJD2A cooperated with ETV1 to increase expression of yes associated protein 1 (YAP1), a Hippo pathway component that itself was associated with prostate tumor aggressiveness.
|
26731476 |
2016 |
|
Mammary Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Altering expression of these microRNAs (miRNAs) regulates KDM4A-dependent TSSG. miRNA inhibition promoted copy gains and increased expression of the drug-resistant oncogene CKS1B, which was further substantiated in primary breast tumors.
|
26755726 |
2016 |
|
Malignant neoplasm of prostate
|
0.090 |
Biomarker
|
disease |
BEFREE |
As Jmjd2a is a histone demethylase, in the current study, we investigated the relationship between interaction Lgr4 with Jmjd 2a and Jmjd2a/androgen receptor (AR) signaling pathway in PCa progression.
|
27743893 |
2016 |